Treatments & Services

Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

 

Bladder

Breast

Colon

Gastrointestinal

Head and Neck

Leukemia

  • Azacitidine +/- Pevonedistat for High Risk MDS, CML, or Low-Blast AML

    A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia


Liver

Lung

  • Pembrolizumab + Epacadostat alone or with Chemotherapy for 1st Line NSCLC

    A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer


Lymphoma

  • Polatuzumab Vedotin with R-CHP versus R-CHOP in DLBCL

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial comparing the efficacy and safety of Polatuzumab Vedotin in combination with Rituximab and CHP (R-CHP) and CHOP (R-CHOP) in previously untreated patients with Diffuse Large B-Cell Lymphoma


  • ABP798 versus Rituximab in Non-Hodgkin Lymphoma

    A Randomized, Double-blind study evaluating the efficacy, safety and immunogenicity of ABP 798 compared with Rituximab in subjects with CD20 postiive B-Cell Non-Hodgkin Lymphoma (NHL)


  • Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

    A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above


  • Rituximab +/- Ibrutinib for Follicular Lymphoma

    A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma


  • TGR-1202 in patients with DLBCL, FL, SLL, or MZL

    A phase 2b randomized study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma


  • Lenalidomide/Rituxan for FL, MZ, ML

    A phase 3b randomized study of Lenalidomide (CC-5013) plus Rituximab maintenance therapy followed by Lenalidomide single-agent maintenance versus Rituximab maintenance in subjects with relapsed/refractory Follicular, Marginal Zone or Mantle Cell Lymphoma


Pancreatic

Prostate

Renal

Solid Tumors